Literature DB >> 9363797

Binding of platelet-activating factor to platelets of Alzheimer's disease and multiinfarct dementia patients.

M Hershkowitz1, A Adunsky.   

Abstract

The binding of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor, PAF) to platelets was studied in 22 patients with probable Alzheimer's disease (AD), 11 with multi-infarct dementia (MID), 22 age-matched normal old controls, and 20 young subjects. The results showed a significantly lower degree of PAF binding to platelets of AD and MID patients than in those of the old controls and young subjects (133.3 +/- 8.5, and 123.4 +/- 16.5 vs. 202.3 +/- 11.6 and 206.7 +/- 17.3 receptors/cell, respectively; p < 0.01). These differences were due to reduced Bmax, while Kd remained unchanged. No significant difference was observed between the PAF binding to platelets of AD and MID patients nor between that of old and young controls. No correlation was found between age and binding in the various elderly groups. However, a significant correlation was found between PAF binding and degree of cognitive impairment in the AD patients. This is the first evidence to support a possible involvement of PAF in dementing disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9363797     DOI: 10.1016/s0197-4580(96)00073-5

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

Review 1.  Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases.

Authors:  Yulong Liu; Lisa B E Shields; Zhongwen Gao; Yuanyi Wang; Yi Ping Zhang; Tianci Chu; Qingsan Zhu; Christopher B Shields; Jun Cai
Journal:  Mol Neurobiol       Date:  2016-09-09       Impact factor: 5.590

2.  Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex.

Authors:  E Francescangeli; A Boila; G Goracci
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

Review 3.  What is the dominant Abeta species in human brain tissue? A review.

Authors:  Gillian C Gregory; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

4.  Lipopolysaccharide-induced cerebral inflammatory damage and the therapeutic effect of platelet activating factor receptor antagonist.

Authors:  Wen-Chao Liu; Wen-Long Ding; Hong-Yu Gu; Ming-Feng Chen; Jin-Jia Hu
Journal:  Neurosci Bull       Date:  2007-09       Impact factor: 5.203

5.  Activation of PAF-synthesizing enzymes in rat brain stem slices after LTP induction in the medial vestibular nuclei.

Authors:  Ermelinda Francescangeli; Silvarosa Grassi; Vito E Pettorossi; Gianfrancesco Goracci
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

Review 6.  From peroxisomal disorders to common neurodegenerative diseases - the role of ether phospholipids in the nervous system.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Johannes Berger
Journal:  FEBS Lett       Date:  2017-09-07       Impact factor: 4.124

Review 7.  Regulation of plasmalogen metabolism and traffic in mammals: The fog begins to lift.

Authors:  Fabian Dorninger; Ernst R Werner; Johannes Berger; Katrin Watschinger
Journal:  Front Cell Dev Biol       Date:  2022-08-31

Review 8.  Plasmalogens, platelet-activating factor and beyond - Ether lipids in signaling and neurodegeneration.

Authors:  Fabian Dorninger; Sonja Forss-Petter; Isabella Wimmer; Johannes Berger
Journal:  Neurobiol Dis       Date:  2020-08-28       Impact factor: 5.996

Review 9.  A Review of Oxidative Stress Products and Related Genes in Early Alzheimer's Disease.

Authors:  Federica Cioffi; Rayan Hassan Ibrahim Adam; Ruchi Bansal; Kerensa Broersen
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.